Related by context. All words. (Click for frequent words.) 80 PANSS 76 Rating Scale MADRS 75 Montgomery Asberg Depression 74 YMRS 73 PANSS total 72 Montgomery Åsberg Depression 72 ADAS cog 70 Negative Syndrome 70 Global Impression 70 MADRS score 69 IRLS 69 CNS LS 69 HDRS 69 HAMD 69 Brief Psychiatric 69 HAQ DI 69 NIH CPSI 68 IBDQ 68 Scale PANSS 67 HAM D# 67 symptom severity 67 ADHD RS 67 subscale scores 67 Global Impression CGI 67 HAM D 67 BPRS 67 UPDRS 66 WOMAC pain 66 Unified Parkinson Disease 66 WOMAC 66 Crohn Disease Activity 65 Hamilton Rating Scale 65 Alzheimer Disease Assessment 65 Index CDAI 65 subscales 65 mTSS 65 Depression Rating Scale 65 depressive symptom 65 Y BOCS 64 PANSS scores 64 DAS# [002] 64 mRS 64 HADS 64 UPDRS motor 64 Visual Analogue Scale VAS 64 IPSS 64 NIHSS 64 ADAS Cog 64 Expanded Disability Status 64 ADCS CGIC 64 Health Assessment Questionnaire 63 QIDS SR 63 Mania Rating Scale 63 -#.# mg dL [002] 63 WOMAC TM 63 International Prostate Symptom 63 BMI z 63 subscores 63 DAS# CRP 63 Scale cognitive subscale 62 Rating Scale 62 SGRQ 62 Inventory BPI 62 nasal symptom 62 HOMA IR 62 Brief Pain 62 CDAI score 62 Secondary endpoints 62 baseline HbA1c 62 Scale EDSS 62 subscore 62 Visual Analog Scale 61 MMSE score 61 Secondary endpoints included 61 Global Impression Severity 61 QoL 61 Rating Scale UPDRS 61 IRLS score 61 Hamilton Anxiety Scale 61 EQ 5D 61 Psoriasis Area 61 placebo p 61 Pain Rating Scale 61 FACIT Fatigue 61 ADCS ADL 61 Physical Component 61 Pain Intensity 61 Visual Analog 61 ADHD Rating Scale 60 Primary endpoints 60 achieved statistical significance 60 CDAI 60 abdominal pain abdominal discomfort 60 -#.# mg dL [001] 60 sd = 60 biopsy Gleason 60 lumbar spine BMD 60 SSRI SNRI 60 Clinician Administered PTSD 60 GERD symptom 60 Disease Activity 60 Fibromyalgia Impact Questionnaire 60 CFQ R 60 PASI scores 60 fasting plasma glucose FPG 60 placebo p = 60 Beck Anxiety Inventory 59 AUA Symptom Score 59 Neuropsychiatric Inventory NPI 59 Depression Inventory 59 Severity Index PASI 59 Score IPSS 59 clinically meaningful improvement 59 Subscale 59 ACR# [002] 59 baseline PASI 59 confidence intervals CIs 59 adjunctive placebo 59 BPH Symptom Score 59 TNSS 59 non menstrual pelvic 59 PSQI 59 State Examination MMSE 59 IIEF 59 ACR# response 58 Secondary efficacy endpoints 58 Score DAS# 58 Neuropsychiatric Inventory 58 oxycodone CR 58 Rating Scale BPRS 58 HbA 1c 58 Severity MSCS score 58 Secondary endpoints include 58 liver histology 58 sUA 58 p = .# [002] 58 demonstrated statistically significant 58 DAS# remission 58 SELENA SLEDAI 58 MoxDuo TM IR 58 Likert pain 58 urinary N telopeptide 58 p = #.# [004] 58 Key secondary endpoints 58 euthymic patients 58 % Confidence Interval 58 SBMs 58 SELENA SLEDAI score 58 BPRS PSS 58 CIBIC plus 58 serologically active patients 57 serum urate 57 Score DAS 57 Negative Symptoms 57 8mg/kg 57 CI -#.# 57 desvenlafaxine succinate 57 EDSS score 57 antipsychotic efficacy 57 #mg/day [001] 57 VFQ 57 ACR# responses 57 Geriatric Depression 57 EDSS 57 baseline A1C 57 pain subscale 57 APACHE II 57 interrater reliability 57 preoperative PSA 57 ANOVA 57 tipranavir r 57 virologic response 57 mg TID 57 point Likert scale 57 p = #.# [002] 57 Main Outcome Measures 57 SSRI citalopram 57 adjunctive ABILIFY 57 baseline FEV 57 apnea hypopnea index 57 -#.# log# copies mL 57 citalopram 57 HRQL 57 log# copies mL 56 SVR# 56 gadolinium enhancing lesions 56 MMSE 56 SLE Responder Index 56 Abnormal Involuntary Movement 56 ACR Pedi 56 -#.# ± [002] 56 extrapyramidal symptoms 56 fasting plasma glucose 56 â ‰ ¥ 56 6MWD 56 posttreatment 56 Mean Symptom Complex 56 plus methotrexate 56 statistically significant improvement 56 methotrexate monotherapy 56 DAS# scores 56 erection hardness 56 linaclotide treated 56 secondary efficacy endpoint 56 = #.#-#.# 56 primary efficacy endpoint 56 affective psychosis 56 demonstrated clinically meaningful 56 ANCOVA 56 DLQI 56 OGTT 56 mg BID dose 56 Depression Scale 56 trough FEV1 56 fructosamine 56 Cronbach alpha 56 Oswestry Disability Index 56 highest tertile 56 Pearson correlation coefficient 56 Symptom severity 56 posttest 56 mcg BID 56 mcg QD 56 NYHA functional class 56 CRp 56 Symptom Score 56 Ocular Surface Disease 56 #.#/#.# mmHg [001] 56 Score TOS 56 RLAI 56 spontaneous bowel movements 55 Depression Inventory BDI 55 budesonide pMDI 55 achieved ACR# 55 HAM D# scores 55 mg qd 55 secondary endpoint 55 clinically meaningful improvements 55 glycosylated hemoglobin HbA1c 55 HRQoL 55 Distress Scale 55 elevated ALT 55 alanine aminotransferase 55 Stroke Scale 55 fasting plasma 55 KOOS 55 REYATAZ r arm 55 #mg/day [002] 55 AUA BPH Symptom Score 55 CORE OM 55 ug kg 55 endoscopic remission 55 mmol l 55 prespecified 55 P = .# 55 ACR# ACR# 55 premorbid 55 periprocedural 55 Stroke Scale NIHSS 55 Depressive Symptomatology 55 venlafaxine XR 55 undetectable HBV DNA 55 plasma leptin 55 Ashworth Scale 55 HRQOL 55 morphometric vertebral fractures 55 Depressive symptoms 55 hip BMD 55 Main Outcome Measure 55 euthymic 55 emotional lability 55 albumin excretion rate 55 hemoglobin A1c HbA1c 55 glycated hemoglobin HbA1c 55 CIMZIA TM 55 PANSS Positive 55 serum testosterone 55 Edinburgh Postnatal Depression 55 Functioning GAF 55 Cmax 55 serum HBV DNA 55 Scale Cognitive Subscale 55 CR nPR 55 psychosocial functioning 55 serum cortisol 55 serum IGF 55 nondepressed 55 intraclass correlation coefficient 55 prednisone prednisolone plus 55 glycated hemoglobin 55 mcg Albuferon 54 plus MTX 54 Pharmacokinetic parameters 54 Epworth Sleepiness Scale 54 depressive symptoms 54 cognitive affective 54 QTcF 54 systolic BP 54 AUC0 54 Cystic Fibrosis Questionnaire Revised 54 mg ustekinumab 54 univariate 54 statistically significant reduction 54 ± SD 54 LOCF 54 x ULN 54 attain statistical significance 54 Negative Symptom Scale 54 plasma folate 54 ng dL 54 Likert scale 54 glycosylated hemoglobin 54 IU mL 54 Scale EDSS score 54 Mental Component 54 mmHg diastolic 54 LEXIVA r 54 annualized relapse 54 subjective sleepiness 54 #.#/#.# mm Hg [003] 54 + PH# 54 Index CDAI score 54 -5 -6 54 intima media thickness 54 intravaginal ejaculatory latency 54 bortezomib refractory 54 nonobese 54 salivary cortisol 54 SF #v# 54 dactylitis 54 4mg/kg 54 symptomatic VTE 54 Ishak fibrosis score 54 intact parathyroid hormone 54 endometrial thickness 54 subthreshold depression 54 treat NNT 54 mg XP# 54 racemic albuterol 54 quetiapine 54 WAIS III 54 ± SEM 54 BILAG 54 blood Phe 54 pretreatment baseline 54 logistic regression analysis 54 SCr 54 PSADT 54 Lucentis monotherapy 54 mg BID 54 receiving ISENTRESS 54 alanine aminotransferase ALT 54 subscale 54 PHQ 9 54 placebo fluoxetine 54 p = 54 log# 54 methacholine challenge 54 tapentadol IR 54 cells uL 54 moderate renal impairment 54 Likert type 54 mg p = 54 certolizumab 54 plasma HCV RNA 54 Pred Forte 54 aPTT 54 sustained virological response 54 adenoma recurrence 54 logistic regression 54 ng dl 54 prespecified secondary 54 left ventricular diastolic 54 Descriptive statistics 54 HBeAg seroconversion 54 receiving golimumab 54 Rating Scale IRLS 54 apnea hypopnea 54 lispro 53 apolipoprotein B 53 LVEF 53 undetectable HCV RNA 53 hemoglobin A1c levels 53 #.#mg/dL 53 Erectile Function IIEF 53 symptomatology 53 % CI #.#-#.# [007] 53 Lupuzor ™ 53 incontinence episodes 53 State Trait Anxiety 53 Kaplan Meier analysis 53 retest reliability 53 serum potassium 53 CSBMs 53 Likert 53 fasting insulin 53 platelet reactivity 53 NIHSS score 53 creatinine ratio 53 Seattle Angina Questionnaire 53 NIS LL 53 clinically meaningful reductions 53 HbA 1c levels 53 Hemoglobin A1c HbA1c 53 TIMI 53 lopinavir r 53 mcg albinterferon alfa 2b 53 HBeAg negative patients 53 CrCl 53 Hb A1C 53 Interrater reliability 53 infliximab monotherapy 53 XIENCE V PROMUS Stent 53 Kaplan Meier estimates 53 PCWP 53 mEq L 53 correlation coefficients 53 tolterodine ER 53 binary restenosis 53 log# reduction 53 biochemical recurrence 53 mg QD 53 Symptom Checklist 53 ARB telmisartan 53 Severity Index 53 Subgroup analysis 53 Rosenberg Self Esteem 53 ug dose 53 odds ratios ORs 53 PREZISTA r arm 53 p = .# [001] 53 somatic symptom 53 preoperatively 53 statistically nonsignificant 53 irbesartan 53 Index HAQ DI 53 HbA1C levels 53 % CI #.#-#.# [003] 53 dichotomized 53 aspartate aminotransferase AST 53 overnight polysomnography 53 Fasting plasma glucose 53 nighttime awakenings 53 retinal thickness 53 dapagliflozin plus 53 eszopiclone 53 TEAEs 53 Anxiety Rating Scale 53 ≥ 53 placebo 53 CSBM 53 Apgar scores 53 HbA 1C 53 NPH insulin 53 Status Scale EDSS 53 TMC# r 53 Pain Inventory 53 Kaplan Meier survival 53 #.#/#.# mm Hg [001] 53 placebo PBO 53 PERMP 53 Knodell necroinflammatory score 53 postprocedure 53 ASIA Impairment 53 oxycodone IR 53 CR CRu 53 Scale CNS 53 multivariate Cox 53 QTc 53 mL/min/#.# m 2 53 Glasgow Coma Scale 53 anemia hemoglobin 53 LS BMD 53 Visual acuity 53 #.#ng/ml 53 ‰ ¥ 53 pramipexole 53 postdose 53 #μg [002] 53 femoral neck BMD 53 -#.# log# 53 solifenacin 53 creatinine clearance 53 Capacity FVC 53 secondary efficacy endpoints 53 serum CRP 53 mm Hg diastolic 53 Wilcoxon rank sum 53 highly emetogenic 53 FSFI 53 untreated psychosis 53 lopinavir r arm 52 univariate analyzes 52 urinary cortisol 52 calculated creatinine clearance 52 definite stent thrombosis 52 UPDRS II 52 mean baseline HbA1c 52 tipranavir ritonavir 52 mcg doses 52 Kaplan Meier 52 total cholesterol LDL 52 primary endpoint 52 FEV1 52 abacavir lamivudine 52 hypoglycemic events 52 active comparator 52 Flu Cy 52 variance ANOVA 52 lowest tertile 52 chlorambucil 52 RECIST Response Evaluation Criteria 52 secondary endpoints 52 timepoints 52 insulin detemir 52 cardiac autonomic 52 HbA1c levels 52 Clinically meaningful 52 progression TTP 52 BENICAR 52 NNT = 52 prospectively defined 52 PSA nadir 52 ALT elevations 52 Primary Endpoint 52 CCyR 52 plasma cortisol 52 nmol liter 52 urinary sodium excretion 52 Wechsler Adult 52 triglycerides TG 52 ACTEMRA TM 52 clomipramine 52 salmeterol fluticasone propionate 52 #mg BID [003] 52 oral glucose tolerance 52 tumor progression TTP 52 mcg linaclotide 52 FDA defined valvulopathy 52 rimonabant #mg 52 mg kg dose 52 serum sodium 52 specific antigen PSA 52 Erectile Function 52 Numeric Rating Scale 52 virological response 52 mean baseline A1C 52 State Exam MMSE 52 serum phosphorus 52 Impressions Improvement 52 statistically significant p 52 ejaculatory control 52 EF Domain 52 timepoint 52 rhinoconjunctivitis 52 adalimumab 52 aminotransferase levels 52 scores TNSS 52 tertiles 52 quetiapine XR 52 nausea photophobia 52 Symptom Severity 52 intraclass correlation coefficients 52 function subscale 52 Functional Assessment 52 serum phosphorous 52 tapentadol ER 52 elevated creatinine 52 postintervention 52 serum HCV RNA 52 Visual Analogue Scale 52 seropositive patients 52 INVEGA ® 52 permanently discontinue Vectibix 52 plus prednisone 52 MMSE scores 52 MCyR 52 corrected QT interval 52 TLUS 52 LDL HDL 52 statistically significant 52 BARACLUDE r 52 Univariate analysis 52 elagolix 52 QRS duration 52 atorvastatin #mg 52 #ng/ml 52 Anxiety Depression 52 nonfatal MI 52 baseline FEV1 52 Incontinence Impact Questionnaire 52 aspartate aminotransferase 52 mcg kg 52 Sensitivity specificity 52 concomitant medications 52 ALIMTA cisplatin 52 dysthymia 51 cEVR 51 ETDRS 51 dose atorvastatin 51 carotid IMT 51 nonsignificant 51 mL sec 51 logistic regression model 51 baseline serum creatinine 51 sham injections 51 tryptophan depletion 51 HER2 expression 51 % CI #.#-#.# [006] 51 diameter stenosis 51 estimated glomerular filtration 51 cells mcL 51 % CI #.#-#.# [005] 51 evaluable subjects 51 subsyndromal 51 EBMT criteria 51 IQR 51 Thrombolysis 51 BPH symptom 51 adefovir treated 51 fasting blood glucose 51 statistically significant p = 51 mg Proellex 51 statistical significance p 51 CIMZIA TM certolizumab pegol 51 achieving PASI 51 Genant modified Sharp 51 fractional anisotropy 51 -#.# mmHg 51 inflammatory lesions 51 Global Impressions Severity 51 IFN α 51 T2DM 51 CIMZIA ™ 51 Response Evaluation Criteria 51 conditional logistic regression 51 virologic failure 51 Dyspnea 51 spud #-#-# drlg [002] 51 Timed Walk 51 hematological parameters 51 unfractionated heparin UFH 51 relapsed MM 51 Female Sexual Function 51 CHADS2 51 mg tid 51 lactate dehydrogenase LDH 51 chi squared 51 atheroma volume 51 CHADS 2 51 sustained virologic response 51 Loss Severity 51 sUA levels 51 Baseline characteristics 51 multivariable Cox 51 manic hypomanic 51 Cockcroft Gault 51 NPRS 51 FACIT 51 hyperarousal 51 REYATAZ r 51 fasting glucose 51 psychosocial variables 51 ATACAND 51 syndromal 51 somatostatin analog 51 blood Phe levels 51 Insulin sensitivity 51 clinically meaningful 51 Kruskal Wallis 51 SBM frequency 51 A1c levels 51 Hemoglobin A1c 51 μg kg 51 urinary albumin 51 Epidemiologic Studies Depression 51 Comorbidity 51 BENICAR HCT 51 covariate 51 multivariable analysis 51 APTIVUS r 51 depressive symptomatology 51 creatine kinase 51 Total Nasal Symptom 51 glomerular filtration rate 51 LV ejection fraction 51 lymphocyte count 51 rosuvastatin #mg 51 P ≤ 51 affective disorders 51 pg mL 51 Hopkins Symptom Checklist 51 #q# deletion syndrome 51 Clinical Dementia 51 fluoxetine 51 erythrocyte sedimentation rate 51 Profile SEP 51 urine albumin 51 antibody titer 51 pmol L 51 μg d 51 ABC/3TC 51 UPDRS Part III 51 Celsentri Selzentry 51 serum concentrations 51 death reinfarction 51 MADRS scores 51 Index WOMAC 51 IELT 51 rs# [004] 51 serum PSA 51 serum triglycerides 51 #mg BID [001] 51 serum urate levels 51 postinjury 51 IU ml 51 -#.# mmol L 51 R# #mg BID 51 haloperidol 51 3mg/kg 51 PREZISTA ritonavir 51 somatization 51 Mini Mental 51 interobserver 51 nondiabetic patients 50 peginterferon alfa 2a 50 saline placebo 50 comparator arm 50 aMCI 50 leukocyte count 50 Neuroticism 50 GOUT 50 corticosteroid dose 50 alteplase 50 per deciliter mg 50 urinary calcium 50 mg simvastatin 50 CHADS 50 CK MB 50 interpersonal psychotherapy IPT 50 ß = 50 mg RDEA# 50 IKDC 50 receiving VICTRELIS 50 glycated hemoglobin levels 50 detectable HCV RNA 50 systolic diastolic 50 fluticasone salmeterol 50 carotid intima media 50 univariate analysis 50 Operative mortality 50 hepatic enzyme 50 paliperidone ER 50 peak expiratory flow 50 multivariate analyzes 50 bivariate 50 QD dosing 50 partial remissions 50 Outcomes Study 50 nmol L. 50 pg ml 50 KCCQ 50 PSA kinetics 50 CI #.#-#.# [001] 50 weekly CSBMs 50 test OGTT 50 achieved PASI 50 NCQA accreditation surveys 50 copies mL 50 Logistic regression 50 divalproex 50 #.#mmol L [002] 50 transaminases 50 nonresponders 50 logMAR 50 Pegasys ® 50 PegIFN RBV 50 serum uric acid 50 noninferiority 50 -#.# ± [001] 50 tirofiban 50 vitreous haze 50 doxorubicin cyclophosphamide 50 mean ± SEM 50 p = #.# [003] 50 tolvaptan 50 SKAMP D 50 #mg QD [002] 50 intima media thickness IMT 50 peak VO2 50 lipid parameters 50 Histologic 50 virologic 50 Pearson correlation coefficients 50 df = 50 PEG IFN 50 postmenopausal osteoporotic women 50 #OHD 50 HbA1C 50 Solid Tumors criteria 50 estimated GFR 50 confirmed CCyR 50 primary endpoints 50 HBV DNA levels 50 hematologic parameters 50 multivariable adjusted 50 hemoglobin A1C 50 dyspareunia 50 hsCRP 50 eplerenone 50 prospectively stratified 50 splenectomized patients 50 Index FSFI 50 Kruskal Wallis test 50 HCV RESPOND 2 50 Likert Scale 50 PASI 50 akathisia 50 avosentan 50 Skin sterol 50 Fasting blood glucose 50 Coronary calcium 50 ULORIC 50 macroalbuminuria 50 fasting serum 50 prolactin levels 50 dyspnoea 50 log# IU mL 50 composite endpoint 50 serum BDNF 50 pCR 50 laboratory abnormalities 50 URTI 50 zonisamide SR 50 Univariate 50 lamivudine refractory patients 50 tiotropium 50 Left Ventricular Ejection Fraction 50 exploratory endpoints 50 Suicidal ideation 50 postop 50 Epidemiological Studies Depression 50 metabolic parameters 50 periprocedural MI 50 cytogenetic response 50 systemic embolism 50 mRNA expression 50 walk distance 6MWD 50 spirometric 50 serum aminotransferase levels 50 GSK# [001] 50 tertile 50 ml kg 50 plus dexamethasone 50 bivariate analysis 50 AUC0 #hr 50 μmol L 50 #mg dose [003] 50 albumin excretion 50 β = 50 hsCRP levels 50 mmol L. 50 hypomanic symptoms 50 decompensation Child Pugh 50 uM 50 major depressive disorder 50 #mg/m# [001] 50 meta regression 50 HBeAg 50 MARINOL R 50 posttransplant 50 pulmonary capillary wedge 50 UACR 50 microgram kg 50 impaired fasting glucose 50 Efficacy endpoints 50 comorbid 50 hypogonadal 50 urate lowering therapy 50 Treatment Outcome 50 gadolinium enhancing 50 IOP lowering 50 risperidone 50 nonparametric 50 umol L 50 Cardiorespiratory fitness 50 Median PFS 50 schizophrenia schizoaffective disorder 50 serum prostate 50 affective psychoses 50 n = 50 ATV RTV 50 thyroglobulin 50 mg Lucentis 50 cTnT levels 50 experienced virologic failure 50 mg eq 50 Kellgren Lawrence 50 FOLPI 50 glycosylated hemoglobin levels 50 CIBIC + 50 UPDRS scores 49 SIMPADICO 49 episodic migraine 49 bepotastine besilate nasal spray 49 amisulpride 49 placebo controlled dose escalation 49 Solid Tumors RECIST 49 doxorubicin docetaxel 49 χ 49 nodular partial response 49 diastolic BP 49 mmol L 49 NLX P# 49 rCBF 49 β blocker 49 Major Adverse Cardiac 49 left ventricular LV 49 primary efficacy endpoints 49 haematologic 49 bivariate analyzes 49 spud #-#-# drlg [003] 49 mL/min/#.# m2 49 genital arousal 49 coronary stenosis 49 neuroleptic 49 multivariable logistic regression 49 lymphocyte counts 49 TPV r 49 Change PGIC 49 viral kinetics 49 oral olanzapine 49 brachial artery flow 49 urinary albumin excretion 49 FEV ^ sub 49 antiretroviral naïve 49 safinamide 49 quartiles 49 echocardiographic parameters 49 certolizumab pegol 49 p = NS 49 radiographic progression 49 angiographic outcomes 49 lacosamide 49 plus OBT 49 biochemical relapse 49 Functional Outcomes 49 extrapyramidal disorder 49 MetS 49 psychometric properties 49 pharmacokinetics PK 49 Bonferroni correction 49 mg/m2 dose 49 binary logistic regression 49 idiopathic Parkinson disease 49 #.#mmol L [001] 49 mL kg 49 Viral load 49 -#.# mm Hg 49 mmHg systolic 49 T2 lesions 49 insulin degludec 49 Treatment Diabetic Retinopathy 49 rotigotine 49 NSTE ACS 49 tranylcypromine 49 alicaforsen enema 49 LDL triglycerides 49 subcutaneous dose 49 phonophobia 49 EORTC QLQ C# 49 WOMAC scores 49 regression coefficient 49 #μg [001] 49 somatic symptoms 49 plasma glucose 49 serum magnesium 49 Engerix B 49 dose dependently 49 comorbid anxiety 49 salmeterol fluticasone 49 ezetimibe simvastatin 49 plasma homocysteine 49 allele frequencies 49 multiple logistic regression 49 antidepressant monotherapy 49 Target Lesion Revascularization TLR 49 Platelet counts 49 events TEAEs 49 intramuscular dose 49 sensitivity specificity 49 serum phosphate levels 49 olanzapine 49 FFNS 49 ribavirin RBV 49 6MW distance 49 CPAP adherence 49 plasma renin activity 49 Hazard Ratio HR